Health Payer Intelligence October 12, 2023
Drug companies and pharmaceutical groups are suing HHS, arguing that the Medicare drug price negotiation rule violates constitutional amendments.
The Medicare drug price negotiation provisions in the Inflation Reduction Act hold promising spending reductions for beneficiaries, but drug companies are not backing down without a fight.
In August 2023, HHS announced the first ten drugs that will be available for Medicare price negotiation starting in 2026. The Department will undergo negotiations with drug companies in 2023 and 2024 for the following drugs: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp and NovoLog drugs.
The drugs treat various conditions, such as blood clots, diabetes, chronic kidney disease, heart failure, rheumatoid arthritis, and blood cancers. Between June 2022 and...